New Delhi: Single dose Bharat Biotech Covaxin in people who have been infected with Covid-19 Previously produce antibody responses that are similar to those provided by two vaccine doses in those who do not have a history of infection, showing a pilot study by the Indian Medical Research Council (ICMR) .
This finding is based on preliminary data and needs to be confirmed with a large-sized cohort study, he said.
This study assumes significance because if the ICMR can validate the initial findings through large-scale studies, can play a role in accelerating coverage.
“This study offers evidence to support the health-oriented vaccine strategy and immunized.
If our initial findings are confirmed in a large population study, a single dose of the BBV152 vaccine can be recommended for people who are infected with SARS-COV-2 which were previously confirmed so that Naive individuals can benefit greater than the supply of limited vaccines, “the short word of paper with research findings published in the Journal of Indian medical research.
However, the author underlines that both vaccine doses will be ideal even for individuals who were previously infected in the long run due to the occurrence of a variant of concern.
Covaxin Bharat Biotech is currently given in a two-dose regimen with a gap of four to six weeks.
The ICMR study was conducted to check the special antibody response of SARS-COV-2 after a zero day (baseline, before vaccination), day 28 (month 1) and day 56 post-first doses (month 2) of covaxin in professional health care groups and line workers front.
Individual antibody responses with pre-vaccinated SARS-COV-2 infections are confirmed compared to individuals without evidence of previous infections.
1 covaxin dose for survivor = 2 doses for not infected
